The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | Strategies used to enhance checkpoint inhibition in Hodgkin lymphoma
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses current strategies used to enhance checkpoint inhibition in Hodgkin lymphoma (HL). Dr Bröckelmann first assesses the combination of standard chemotherapy agents or radiotherapy with an anti-PD1 inhibitor, and highlights clinical trials in this space. Following this, Dr Bröckelmann comments on the importance of investigating other combinations that may target different checkpoints in HL. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Research funding: BeiGene, Bristol-Myers Squibb, MSD, Takeda
Advisory boards: Takeda
Speakers’ bureau: BeiGene, MSD
